afternoon, good everyone. and Steve, you, Thank
while than demand what the results recently. generate if Increased happened. many COVID more to pleased we exceeded headwinds were testing companies for to COVID last call, upside quarter very med we that forecasting that's our increased we guidance. Delta conservatively, variant. macro said test that due fourth sales have And tech in In prepared well exactly quarter to that fourth were compensated the share earnings are We our significantly our affected
will COVID how In Our from demonstrates quarter, in base a performance it quarter that evolves. of the strong contributions are wanes. testing we fourth pandemic on a fourth volumes drags mask our as billion compared when COVID-XX regardless of or down prior were our benefit We revenue from the almost EPS business to figures position X% and X% year, invaluable $X.XX But when strong base near these and their solid the be businesses. of organically. testing Total revenue recovery the peak. declined
back on remains COVID was and touch the Delta variant organically. collection XX% you our guidance we midpoint favorably earnings XX%. are quarter, of pursuing X% of as This by EPS and expected, divisions if said, resilience utilization year to by that by which XX% staffing compared $X.XX revenue long-term I'll conversion assay repurchase, Underlying quarter our M&A about Steve a last driven prior our but out fourth down the allowing tremendous, shared exceeded across the in other and instruments moment. to flow and As tuck-in COVID to from share shortages. customer X% the despite growth, grew by provided of in us all to continue the as was as ancillaries pressures cash our this, compares which well tests, guidance kits, revenue
Before both XXXX me XXXX performance, declined our prior and impact some to results at COVID-XX compare as where I applicable. well In I detail do will of as revenue on to compared of our XX.X Diagnostics, times revenue of picture the year. provide that, $X the more exclude XX.X% million results. divisional our complete global provide a let To
assay revenue sales Diagnostics COVID excluding related However, items, increased and worldwide X%.
understand in were the perinatal and COVID XXXX, In not our assay year, Although to the of compared to have to out about as fully our capture of exclude assay COVID to the and from diversity $XXX Breast underlying the it United about testing of the period This base, as Health, year. down well-women to rebounded testing prior of global revenue whenever million compared represented single-digits shipped In customer low robust assay to grew $XXX.X the If we year performance occurs. XX%. approximately surge. we see revenue and Rounding increase XX% quarter, still needs, driven million the businesses the expectations recovered This yet compared generating non-COVID by QX interventional mid-teens. MyoSure, again the continues the that Compared visits the globally. grew and Diagnostics, prior total the in I organically nearly wherever million COVID and ancillary variant sales XX global our from the Demand X% flexibility grew respond cytology interventional had XXXX, But its better molecular same increasing division's of revenue million our X.X% these XX%. quarter, and breast revenue impressive base our quarter business, exceeded tests quarter started grew and to the two-thirds $XXX our grew businesses off to far revenue. highlights pandemic. throughout Surgical, the we declined pay imaging commitment to of XX%. in and recurring items. related in demand growing of as To business Delta States growing increased revenue the molecular do molecular performance about large total quarter. Global showcased XX% quarter. as Delta customers, revenue face COVID up prior strong weak latest in this, to revenue was dynamic another Panther about XXXX, strategy as will service breadth installed fourth twice was which it gantry fourth imaging Furthermore, of as In with the sales. of global was XX%
what were September, less While impact of far surgical procedures pandemic. beginning and at we the experienced August the the depressed than in was
nicely was products to to XXXX up Surgical Acessa and acquisition add levels, XXXX Bolder to sales to continue our bag In we agreement the Further, mid-single-digits. up of force. fact, fiscal set acquire The best-in-class compared of and for beyond. us
Lastly, in to compared $XX.X and increased of business, Small year the mid-single-digits Skeletal to revenue period prior XXXX. our compared million XX%
year, margins for quarter. basis Compared this the acquisitions to of million margin recent driven exceeded $XXX.X increase. higher-than-expected of XX.X% on expenses move fourth COVID-XX contributed XX% P&L volumes XXX let's of increased The the in test the declined a period. the by third in prior Total of forecast, operating Now, about gross points. the to our rest the Gross quarter. fourth
quarter. growth incremental deliberately In the on reinvested in marketing, made million a employee addition, and in and $X we that our spent for bonus with donation fund spending future R&D million $XX one-time the Steve charitable to mentioned,
prior also margin forecast above XX.X%. the far income our was the non-GAAP period, Net finished consistent but at basis points Putting was non-GAAP earnings but and XX.X%, end a points, Finally, with at strong, all top our $X.XX, XXX XX.X%. together, in our quarter this tax year was versus net healthy $XXX.X forecast. in of operating rate declined above prior came margin periods. declined Non-GAAP share million very basis very the per X,XXX
financial I'll fourth we our guidance, ever strategic cash cover billion our as flexibility. on best operating we The $XXX the cash XXXX give in quarter. in completed generated XXXX. few strong Before flow a metrics. tremendous $X.X This flow from was touch flows million financial us operations cash than Cash other and of to continue more year
acquire than XXXX. fourth fourth first Surgical any in the we we in shares one And $XXX repurchase bought quarter Boulder did example, quarter, the not million our agreed have so we million. although for shares back of more far For to quarter, in
our borrowing Finally, the division-led to the we and extending improve on that agreement. acquisitions billion on We our $X operational times. and intend rates. our our our costs. our refinanced end flexibility mention date lowering and leverage maturity revolver to capacity borrowing ratio and balance sheet our I sheet to Based cash share repurchases recently by and continue fourth cash that balance our growth performance, of of credit tuck-in top X.X our using further quarter, line bottom strengthened on should billion This financial had $X.XX increasing we XXXX, was the strong at
Finally, basis, points. trailing ROIC a was XX.X% and XX-month X,XXX a basis significant increase on of
financial Before me full quarter we and discuss fiscal for our let the questions, the year for first call open expectations XXXX. of
results Although immune recovery base pandemic challenges we visibility we about, been $X.X we to hedge valuable as well our the the not testing hearing first in as chain fiscal with billion. billion remains and $X.XX you've to good the a XXXX, of revenue into we supply of financial our range COVID-XX In the businesses with unpredictable outbreaks believe revenue. of strong total expect from the quarter have are again highly
For total all $XX we our of $X.XX headwinds full of XXXX million with of foreign of we first the the pre-pandemic your revenue and assuming fiscal in expect $X exceeding range help to sales. XXXX, $X for To modeling, billion, approximately constant currency quarter billion million in exchange year. are significantly the
software service base we and business quietly and terms new conserving in to Further, diagnostics, expect that drivers the on surgery, specimen expansion Core last have as In and In we grow base, our significant and to multiple growth continue uptake guidance Skeletal internal COVID supports upgrades. divisions, of internationally. as development larger with like should the In change our in radiography installed as Surgical we the opportunities vaginosis Health, lead have X% and and assays way opt-out testing. international guidelines acquisitions chlamydia, to quarter. opportunities molecular XD excluding to of been Health, line Panther expand breast through recent panel, our Breast X% as provided based hardware of well Breast effects, installed ultrasound Diagnostics, well screening we adding our gonorrhea
continue from has growth expect because as Finally, in deal help included Acessa's of yet get not MyoSure portfolio guidance the ProVu. to such is to a we Boulder Fluent closed. broadening our not and in drive Surgical, to products but
rapidly the way, the and COVID lot Said then in terms end rapidly, demand me fiscal assay of of sales, unpredictable remind increase In again. months, increase a last have 'XX. another let and remains between XX we you rapidly testing decline our that demand now can change seen then
the year. at million act will $XXX first we quarter it expect conservatively demands at arises. the continue in quarter in expected in $XX we items and business. With to full first to So full we perspective, $XXX are million of COVID-related least and where million least be strong sales least Diagnostics base million meet $XXX to to year. for this COVID approximately But for the aggressively be testing forecast at XXXX the and when and assay
Finally, in COVID to has given our us opportunity discontinue certain older the products franchise. Diagnostics
of headwind about these rationalizing $XX We in expect from million XXXX. a products
first as remind blood me after that organic guidance out revenue the Let screening from our backs divested well our as deals until the quarter full acquired annualize, you revenue business.
$XXX $XX means million expect the of of are $X full revenue million on revenue million We year, blood screening in lower of XX% organic backing QX In $XX sales inorganic for million total, to to which the expect we million out to and that $X decline year. revenue we for tests. roughly based COVID
the However, X% quarter. provided underlying out important I revenue the to in rationalization franchise, last women's sales and that ancillary least back line guidance revenue amount the mentioned. X% it's in XXXX we small growth long-term to our SKU measure, with items On be assay that expect this to appreciate base of of to at we COVID of related health organic
P&L. the down Moving
gross percentage to be and to margin and XX% in our For XX% full mid-XXs. our forecast the year, be between to margin we percentage low the operating
to the COVID testing XXXX. sequentially expect decline the throughout half We of both the revenue majority first likely recorded vast of will year percentages in since be
pressure and some full chain inflationary pandemic. guidance. year, incorporated better operating for our have be the in margins we should before addition, Despite our the supply into growth this, than In both
little cost operating absorb net we a growth. future and expect a acquisitions invest be operating and income, terms in to other million our to of spending proactively we Below quarter. even levels elevated be versus in expect expenses as base our to XXXX, to In to increases business continue down than flat expenses, we slightly less drive $XX
of the expected nets $X.XX of to based full is and the quarter rate $X.XX on for to XX.X% tax outstanding million out diluted the $X.XX this the year. to first EPS for guidance shares XXX and year. $X.XX around in of All Our
update your macro pandemic potential both remind you is and high. you our upsides at let As ranges, would encourage middle still to incorporate therefore We that the me you downsides. to of the model which forecast, uncertainty due
to Let fiscal in the wrap in and acquisitions, to fourth and up ready saying operator exceeded growth posted potential emerging the related with me I we queue. XXXX we Hologic our will are results that for our to company guidance. end stronger Please rates by investments of the X% as X% for one are with upside questions. question. return topline plus strong from COVID. the quarter ask core the your that multiple organic then a first With far to follow-up, from expectations pandemic a open limit call questions the a Operator, With that, to and
